Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11960281 | 0.90 | CNR2 (0.41) | CNR2NPC1KDM4ELMNAMAPT | |
| SCHEMBL17070006 | 0.90 | CNR2 (0.41) | CNR2NPC1KDM4ELMNAMAPT | |
| SCHEMBL13925254 | 0.89 | CNR2 (0.53) | CNR2NPC1KDM4ELMNAMAPT | |
| SCHEMBL13541267 | 0.89 | CNR2 (0.53) | CNR2NPC1KDM4ELMNAMAPT | |
| SCHEMBL23802421 | 0.88 | CNR2 (0.38) | CNR2NPC1KDM4ELMNAMAPT | |
| SCHEMBL21431251 | 0.87 | KDM4E (0.45) | CNR2NPC1KDM4ELMNAMAPT | |
| SCHEMBL23801788 | 0.87 | CNR2 (0.43) | CNR2NPC1KDM4ELMNAMAPT | |
| SCHEMBL23801780 | 0.87 | CNR2 (0.43) | CNR2NPC1KDM4ELMNAMAPT | |
| SCHEMBL13863496 | 0.86 | KDM4E (0.50) | CNR2NPC1KDM4ELMNAMAPT | |
| SCHEMBL12890838 | 0.86 | CNR2 (0.40) | CNR2NPC1KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021175855-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | OCIAD1, OCIAD2, OXER1 | CNR2 663/4885NPC1 4686/4885KDM4E 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.